

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2012

	Current Quarter Ended 30.9.2012 (Unaudited) RM'000	Corresponding Quarter Ended 30.9.2011 (Unaudited) RM'000	Current Year-To-Date Ended 30.9.2012 (Unaudited) RM'000	Corresponding Year-To-Date Ended 30.9.2011 (Unaudited) RM'000
Revenue	8,174	7,701	24,274	23,147
Operating profit	2,798	2,667	7,966	8,182
Operating expenses	(2,008)	(1,987)	(6,002)	(5,914)
Finance costs	(106)	(125)	(327)	(358)
Profit before taxation	684	555	1,637	1,910
Tax expense	(173)	(124)	(467)	(440)
Profit after taxation	511	431	1,170	1,470
Other comprehensive income, net of tax	2	(1)	8	4
Total comprehensive income	513	430	1,178	1,474
Profit after taxation attributable to Owners of the Company:	511	431	1,170	1,470
Total comprehensive income attributable to Owners of the Company:	513	430	1,178	1,474
Earnings per share (sen) attributable to Owners of the Company:				
- Basic	0.34	0.29	0.78	0.98

Note:-

The above condensed consolidated statements of comprehensive income should be read in conjunction with the audited financial statements for the financial year ended 31 December 2011 and the accompanying explanatory notes attached to the interim financial statements.

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
AS AT 30 SEPTEMBER 2012

	As At Current Year Quarter 30.9.2012 (Unaudited) RM'000	As At Financial Year End 31.12.2011 (Audited) RM'000
ASSETS		
Non - current assets		
Property, plant and equipment	16,543	16,276
Product development expenditure	499	760
Goodwill	58	58
Quoted investments	-	5
	<u>17,100</u>	<u>17,099</u>
Current assets		
Inventories	11,066	9,557
Trade receivables	6,839	6,390
Other receivables, deposits and prepayments	408	730
Tax refundable	26	194
Fixed and short term deposits with licensed banks	3,360	3,289
Cash and bank balances with licensed banks and other financial institution	5,387	7,086
	<u>27,086</u>	<u>27,246</u>
TOTAL ASSETS	<u>44,186</u>	<u>44,345</u>
EQUITY AND LIABILITIES		
Equity		
Share capital	14,939	14,939
Share premium	3,520	3,520
Treasury shares	(2)	-
Retained profits	17,475	16,305
Fair value reserve	-	*
Revaluation reserves	3,178	3,178
Merger deficit	(8,397)	(8,397)
Currency translation reserve	(21)	(29)
	<u>30,692</u>	<u>29,516</u>
Non-current liabilities		
Deferred taxation	637	580
Hire purchase payables	112	218
Term loans	4,983	5,377
	<u>5,732</u>	<u>6,175</u>
Current Liabilities		
Trade payables	4,149	3,311
Bill payable	1,683	3,101
Other payables and accruals	1,267	1,575
Amount owing to directors	2	2
Hire purchase payables	141	135
Term loans	520	499
Provision for taxation	-	31
	<u>7,762</u>	<u>8,654</u>
TOTAL LIABILITIES	<u>13,494</u>	<u>14,829</u>
TOTAL EQUITY AND LIABILITIES	<u>44,186</u>	<u>44,345</u>
Net assets per share (RM) attributable to owners of the Company	<u>0.21</u>	<u>0.20</u>

Note:-

* RM650

The above condensed consolidated statements of financial position should be read in conjunction with the audited financial statements for the financial year ended 31 December 2011 and the accompanying explanatory notes attached to the interim financial statements.

The net assets per share attributable to owners of the Company is calculated based on net assets value and the issued paid up share capital of 149,380,500 shares (149,390,500 shares - 2011) excluding treasury shares.

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2012

	←			Non-distributable			→		Distributable	
	Share Capital RM'000	Share Premium RM'000	Treasury Shares RM'000	Fair Value Reserve RM'000	Revaluation Reserves RM'000	Merger Deficit RM'000	Currency Translation Reserve RM'000	Retained Profits RM'000	Total Equity RM'000	
9 months ended 30 September 2012										
(Unaudited)										
Balance at 1 January 2012	14,939	3,520	-	*	3,178	(8,397)	(29)	16,305	29,516	
Total comprehensive income for the financial period	-	-	-	**	-	-	8	1,170	1,178	
Purchase of treasury shares	-	-	(2)	-	-	-	-	-	(2)	
Balance at 30 September 2012	14,939	3,520	(2)	-	3,178	(8,397)	(21)	17,475	30,692	
9 months ended 30 September 2011										
(Unaudited)										
Balance at 1 January 2011	14,939	3,520	-	5	3,179	(8,397)	-	15,219	28,465	
Total comprehensive income for the financial period	-	-	-	4	-	-	-	1,470	1,474	
Tax-exempt dividend	-	-	-	-	-	-	-	(672)	(672)	
Balance at 30 September 2011	14,939	3,520	-	9	3,179	(8,397)	-	16,017	29,267	

Note:-

- * RM650
- ** (RM650)

The above condensed consolidated statements of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 31 December 2011 and the accompanying explanatory notes attached to the interim financial statements.

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2012

	Current Year To Date Ended 30.9.2012 (Unaudited) RM'000	Corresponding Year To Date Ended 30.9.2011 (Unaudited) RM'000
Cash flows from/(for) operating activities		
Profit before taxation	1,637	1,910
Adjustments for:-		
Amortisation of product development expenditure	184	187
Depreciation of property, plant and equipment	467	391
Interest expense	309	336
Inventories written off	116	260
Product development expenditure written off	77	-
Plant and equipment written off	3	-
Gain on disposal of plant and equipment	(1)	(46)
Gain on disposal of quoted shares	(2)	-
Interest income	(72)	(100)
Unrealised (gain)/loss on foreign exchange	(119)	59
Operating profit before working capital changes	<u>2,599</u>	<u>2,997</u>
Increase in inventories	(1,626)	(479)
Increase in trade and other receivables	(123)	(414)
Decrease in trade and other payables	(772)	(155)
Cash from operations	<u>78</u>	<u>1,949</u>
Net tax paid	(272)	(382)
Interest paid	(311)	(332)
Net cash from/(for) operating activities	<u>(505)</u>	<u>1,235</u>
Cash flows from/(for) investing activities		
Interest received	72	100
Purchase of property, plant and equipment	(738)	(784)
Proceeds from disposal of plant and equipment	1	47
Proceeds from disposal of quoted investment	6	-
Net cash for investing activities	<u>(659)</u>	<u>(637)</u>
Cash flows from/(for) financing activities		
Drawdown of term loans	-	665
Repayment of term loans	(370)	(220)
Repayment to directors	-	(46)
Repayment of hire purchase obligations	(100)	(66)
Payment of dividend	-	(1,568)
Share buy-back	(2)	-
Net cash for financing activities	<u>(472)</u>	<u>(1,235)</u>
Net decrease in cash and cash equivalents	(1,636)	(637)
Cash and cash equivalents at beginning of the financial period	10,375	11,400
Foreign exchange difference	8	-
Cash and cash equivalents at end of the financial period	<u>8,747</u>	<u>10,763</u>
Cash and cash equivalents comprise:		
Fixed and short term deposits with licensed banks	3,360	3,266
Cash and bank balances with licensed banks and other financial institution	5,387	7,497
	<u>8,747</u>	<u>10,763</u>

Note:-

The above condensed consolidated statements of cash flows should be read in conjunction with the audited financial statements for the financial year ended 31 December 2011 and the accompanying explanatory notes attached to the interim financial statements.